MHB 018A
Alternative Names: MHB-018ALatest Information Update: 08 Dec 2025
At a glance
- Originator Minghui Pharmaceutical (Shanghai)
- Class Eye disorder therapies; Immunoglobulin Fc fragments; Recombinant fusion proteins; Single-domain antibodies
- Mechanism of Action IGF type 1 receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Graves ophthalmopathy
Most Recent Events
- 03 Dec 2025 Minghui Pharmaceutical (Shanghai) plans a phase III open-label extension trial for Graves ophthalmopathy in China (SC, Injection), in January 2026 (NCT07262476)
- 22 Jul 2025 Phase-III clinical trials in Graves ophthalmopathy in China (SC) (NCT06989918)
- 22 Oct 2024 Minghui Pharmaceuticals plans a phase III trial for Graves ophthalmopathy, in August 2025 (SC) (NCT06989918)